The Prosigna gene expression assay and responsiveness to adjuvant cyclophosphamide-based chemotherapy in premenopausal high-risk patients with breast cancer

BACKGROUND: The PAM50-based (Prosigna) risk of recurrence (ROR) score and intrinsic subtypes are prognostic for women with high-risk breast cancer. We investigate the predictive ability of Prosigna regarding the effectiveness of cyclophosphamide-based adjuvant chemotherapy in premenopausal patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Jensen, Maj-Britt, Lænkholm, Anne-Vibeke, Nielsen, Torsten O., Eriksen, Jens Ole, Wehn, Pernille, Hood, Tressa, Ram, Namratha, Buckingham, Wesley, Ferree, Sean, Ejlertsen, Bent
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6062869/
https://www.ncbi.nlm.nih.gov/pubmed/30053900
http://dx.doi.org/10.1186/s13058-018-1012-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6062869/
https://www.ncbi.nlm.nih.gov/pubmed/30053900
http://dx.doi.org/10.1186/s13058-018-1012-0

Ejemplares similares